
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Shares of Altimmune, Inc. (NASDAQ:ALT) fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.